Equillium initiated with an Outperform at SVB Leerink. SVB Leerink analyst Pasha Sarraf initiated Equillium with an Outperform rating and $16 price target, stating that CD6, which the company is targeting, is a “surprisingly underdeveloped biological pathway” to regulate runaway autoimmunity.
https://thefly.com/landingPageNews.php?id=2868729
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.